Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Twist Bioscience Corporation - Common Stock (NQ: TWST )

47.59 +0.72 (+1.54%)
Streaming Delayed Price Updated: 4:00 PM EST, Feb 14, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 809,219
Open 47.50
Bid (Size) 47.60 (1)
Ask (Size) 48.07 (1)
Prev. Close 46.87
Today's Range 46.81 - 48.34
52wk Range 27.41 - 60.90
Shares Outstanding 50,885,068
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Cathie Wood's Ark Invest Loads Up On Iridium, Twist Bioscience, Offloads Roku: Here Are Key Ark Trades This Friday
Cathie Wood-led Ark Invest made trades involving IRDM, TWST, PD, BEAM, ROKU, and IBTA. 
Via Benzinga
Cathie Wood Dumps $16 Million Worth Of Palantir Stock After Record Highs
On Monday, February 10, 2025, the Cathie Wood-led Ark Invest sold nearly $16 million worth of Palantir shares amid a spike in the share price of the company. 
Via Benzinga

Performance

YTD
+5.03%
+5.03%
1 Month
+3.75%
+3.75%
3 Month
+14.87%
+14.87%
6 Month
+7.21%
+7.21%
1 Year
+16.39%
+16.39%

More News

Read More
Cathie Wood's Ark Invest Bets Big On Amazon, Roblox And Illumina While Trimming Palantir Stake After Alex Karp-Led Company Touched An All-Time High On Thursday
Via Benzinga
Forecasting The Future: 6 Analyst Projections For Twist Bioscience
Via Benzinga
Top Wall Street Forecasters Revamp Twist Bioscience Price Expectations Ahead Of Q4 Earnings
Via Benzinga
Twist Bioscience Earnings Preview
Via Benzinga
Twist Bioscience Announces Fiscal 2025 First Quarter Financial Results
From Twist Bioscience Corporation
Via Business Wire
Earnings Scheduled For February 3, 2025
Via Benzinga
Twist Bioscience to Report Fiscal 2025 First Quarter Financial Results on Monday, February 3, 2025
From Twist Bioscience Corporation
Via Business Wire
Twist Bioscience to Present at 43rd Annual J.P. Morgan Healthcare Conference
From Twist Bioscience Corporation
Via Business Wire
Cathie Wood Sees Tesla As 'Largest AI Project On Earth' — Here's Why She's Not Worried About Tech Investments
Via Benzinga
Topics Artificial Intelligence
Exposures Artificial Intelligence
Cathie Wood Sees $400B Opportunity In Biologics — How Have Her Bets Fared?
Via Benzinga
Topics Artificial Intelligence
Exposures Artificial Intelligence
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
Crude Oil Rises Sharply; US Homebuilder Sentiment Surges In November
Via Benzinga
Exposures Fossil Fuels
Twist Bioscience's Q4 Earnings And Q1 Guidance Surpass Expectations, Stock Jumps
Via Benzinga
Twist Bioscience Posts Upbeat Results, Joins Tesla, Amylyx Pharmaceuticals, Regenxbio And Other Big Stocks Moving Higher On Monday
Via Benzinga
Twist Bioscience Announces Fiscal 2024 Fourth Quarter and Full Year Financial Results
From Twist Bioscience Corporation
Via Business Wire
Earnings Scheduled For November 18, 2024
Via Benzinga
Twist Bioscience to Present at 7th Annual Evercore HealthCONx Conference
From Twist Bioscience Corporation
Via Business Wire
Twist Bioscience Corporation Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
From Twist Bioscience Corporation
Via Business Wire
Cathie Wood's Ark Innovation, Genomic ETFs Celebrate 10 Years: How Annual Returns Stack Up Against S&P 500
Via Benzinga
Topics ETFs Stocks
Exposures US Equities
Absci and Twist Bioscience Collaborate to Design Novel Antibody using Generative AI
From Absci Corporation
Via GlobeNewswire
Twist Bioscience Launches FlexPrep™ Ultra-High Throughput Library Preparation Kit for Applications in Agrigenomics and Population Genomics
From Twist Bioscience Corporation
Via Business Wire
Twist Bioscience to Report Fiscal 2024 Fourth Quarter and Full Year Financial Results on Monday, November 18, 2024
From Twist Bioscience Corporation
Via Business Wire
Twist Bioscience Enters into Royalty Purchase Agreement with XOMA Royalty for $15 Million in Cash
From Twist Bioscience Corporation
Via Business Wire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.